Exclusive Summary

• - Patent/data exclusivities in most key markets have expired or will phase out during 2024–2026, with first generic approvals appearing, creating a near-term entry window.
• - The 5 mg IR strength covers RA/PsA standard maintenance and UC maintenance; oral small molecule convenience can substitute part of injectable biologics in cost-sensitive settings.
• - Large addressable populations (RA >20 million, UC >3 million) and consistent demand after csDMARD/anti-TNF failure support sustained uptake.
• - Dual models (Distribution and Technology Transfer) enable fast-to-market entry and localization for tender/access advantages.
• - Versus originator, generics can reduce costs by 80–95% in emerging markets and by 50–80% in mature markets post-launch, improving affordability for payers and self-pay.